Dr. Jin Wang is currently a Professor in the Department of Breast Oncology at SYSUCC. She specializes in breast oncology and is a renowned young oncological surgeon in China. Dr. Jin Wang graduated from Peking Union Medical College and obtained M.D. degree in 2012, and then worked as a surgeon at SYSUCC. From 2019 to 2020, Dr. Jin Wang had been a Postdoctoral Fellow in the Department of Surgical Oncology, Massachusetts General Hospital, Harvard University. Dr. Jin Wang has led various projects, including the National Natural Science Foundation of China, Guangdong Province Natural Science Foundation, Guangdong Province Medical Research Fund, the Guangzhou Science and Technology Plan projects, and the Sun Yat-sen University Young Talent Program.

Clinical Research: 1) Breast plastic and reconstructive surgery; 2)Endoscopic breast cancer surgery; 3)Neoadjuvant therapy for breast cancer; 4)Immunotherapy for breast cancer;5) Targeted therapy for breast cancer.

Basic and Translational Research: 1) Mechanism of the growth and metastasis of breast cancer; 2) Nanoparticle biotechnology;3) Application of AI in diagnosis and treatment of breast cancer

2012, Doctor of Clinical Medicine

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

2020, Postdoctoral Fellow

Department of Surgical Oncology, Massachusetts General Hospital, Harvard University

1. Zou Y, Yang A, Chen B, Deng X, Xie J, Dai D, Zhang J, Tang H, Wu T, Zhou Z, Xie X, Wang J*. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resist Updat. 2024 Aug 6;77:101126.

2. Wang Z#, Yang L#, Wu P#, Li X#, Tang Y, Ou X, Zhang Y, Xiao X, Wang J*, Tang H*. The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer. 2022 Jan 24;21(1):29.

3. Tang H^#, Huang X^#, Wang J^#, Yang L, Kong Y, Gao G, Zhang L, Chen ZS, Xie X*. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer. 2019;18(1):23.

4. Wang J^#*, Tang H^#, Li X, Song C, Xiong Z, Wang X, Xie X, Tang J*. Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy? Cancer Commun. 2019;39(1):25.

5. Zhang J, Guan H, Song C, Liu L, Tang H, Wang J*. Locoregional treatments of metastatic internal mammary node following neoadjuvant chemotherapy. Chin Med J. 2025;138(3):358-360.

6. Wang J#*, Tang H#, Yin K#, Li X, Xie X, Hughes KS*. Second invasive breast cancers in patients treated with breast-conserving therapy. Eur J Surg Oncol. 2021 Oct;47(10):2492-2498.

7. Yutian Zou, Lei Bian, Hanqi Zhang, Hailin Tang, Cheng Peng, Jin Wang*. ASO Author Reflections: Limited Survival Benefit from Neoadjuvant Chemotherapy in ER+/HER2- Breast Cancer. Ann Surg Oncol. 2025 Sep;32(9):6687-6688.

8. Wang J^#*, Song C^#, Tang H^#, Zhang C, Tang J, Li X, Chen B, Xie X*. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 2017;19(1):72.

9. Chen B^#, Wang J^#, Dai D^#, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X*. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. J Exp Clin Cancer Res. 2017;36(1):65.

10. Wang J^#*, Zhang C^#, Tang H^#, Tang H, Tang J, Song C, Xie X*. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:255-269.

11. Wang J*, Yang B, Bian L, Zhang H, Peng C, Zou Y, Tang H. Long-term Outcomes for Neoadjuvant Versus Adjuvant Chemotherapy in ER+/HER2- Locally Advanced Breast Cancer. Ann Surg Oncol. 2025 Jul;32(7):4890-4898.